# Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

> **NCT00143572** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 16 (actual)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** Magnesium Pidolate, Hydroxyurea

## Key facts

- **NCT ID:** NCT00143572
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143572, "Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00143572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*